cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Neural Therapy in Patients With Fibromiyalgia

Neural therapy is a regulation therapy that tries to correct this underlying autonomic dysfunction. In neural therapy; local painful areas, trigger points and symptomatic segments are included in the injection using local anesthetics and the underlying disruptive areas are investigated and treated. The aim of this study was to investigate the efficacy of neural therapy in fibromyalgia syndrome which is thought to have a neuroendocrine dysregulation disorder.

Fibromyalgia is a chronic disease characterized by widespread body pain, fatigue, sleep disturbance, and tenderness on palpation at trigger points in the musculoskeletal system.

Fibromyalgia prevalence is reported between 3% and 9%, and is three times more common in women than men. Although pharmacological and non-pharmacological approaches play a role in the treatment of the disease, the interest in non-pharmacological therapies has recently increased. In several studies, it has been shown that almost every fibromyalgia patient has applied at least one alternative and complementary medicine method such as Qigong, Tai Chi, yoga, mind body interventions, acupuncture, hydrotherapy, balneotherapy or phytotherapy.

Neural therapy is a regulation therapy that tries to correct this underlying autonomic dysfunction. In neural therapy; local painful areas, trigger points and symptomatic segments are included in the injection using local anesthetics and the underlying disruptive areas are investigated and treated. The aim of this study was to investigate the efficacy of neural therapy in fibromyalgia syndrome which is thought to have a neuroendocrine dysregulation disorder.

Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed according to the American College of Rheumatology 2016 diagnostic criteria for fibromyalgia.

Exclusion Criteria:

* History of comorbid inflammatory rheumatic/ connective tissue diseases
* History of cardiovascular or musculoskeletal problems that could prevent them to participate in an exercise program
The Effect of Polycystic Ovary Syndrome on Pelvic Floor Structure and Function

Polycystic Ovarian Syndrome (PCOS) is the most common endocrinological disorder in women of reproductive age, and its prevalence is reported to be 6-21% in women aged 15-49 (1). Although its etiopathogenesis is still not clear, it is known that it is due to the disregulation of ovarian steroidogenesis under the influence of some environmental and genetic factors. Diagnosis of ESHRE / ASRM has set Rotterdam criteria in 2003; one of these criteria is the presence of hyperandrogenism (2). Hyperandrogenism leads to an increase in general muscle mass in the body (1, 3, 4).

Pelvic floor muscles are associated with urethra in the anterior compartment, rectum and anus in the posterior compartment, and uterine support in the apex; major urinary and fecal continence ensuring its functions in order to stop in the appropriate position of the pelvic organs (5). The well-being of the pelvic floor muscle strength has a protective effect from urinary and fecal incontinence.

It has been emphasized that the "anogenital distance" determined by the measurement of the anal region anterior to the clitoris anterior may also be a criteria in the diagnosis of Polycystic Ovary Syndrome (7,8,9).

In this study, patients in the reproductive age between 18-40 years, who applied to our gynecology outpatient clinic and were diagnosed as PCOS according to Rotterdam criteria wil be study gorup and the women without PCOS will be control group. We aimed to evaluate the pelvic muscle strength with perineometry, to measure anogenital distance and to determine possible relationships with each other. In addition to demographic information, ICIQ-SF (Urinary incontinence inquiry short form) will also be taken to evaluate pelvic floor function (10).


Eligibility Criteria:
Inclusion Criteria:

* Nulliparity

Exclusion Criteria:

* Endocrine disorders
* Anabolic drug usage Multiparity
The Relationship Between Flexibility and Rowing Performance on Elite Rowers

The aim of the research is to examine the effects of ankle, low back and hamstring flexibility of young male rowers on 2000-m rowing performance. Research data were collected on January 8, 2023, at Turkey Indoor Rowing Championship. The subjects of the research (n=26) is young male rowers aged 16-18 and with at least 2 years of rowing age. Outcome measures in this study are 'Sit and Reach Test' and 'Weight Bearing Lunge Test'.

The aim of the research is to examine the effects of ankle, low back and hamstring flexibility of young male rowers on 2000-m rowing performance. Research data were collected on January 8, 2023, at Turkey Indoor Rowing Championship.The study included 26 male rowers who competed in different Turkish rowing teams. The subjects completed a form requesting certain personal and training data also consent form was filled. After subject completed the form, flexibility of the back and backline of lower extremities were measured. To measure the low back and hamstring muscle flexibility, 'sit and reach test' and assess the ankle flexibility 'weight bearing lunge test' were conducted on each rower. In order to measure performance of rowers, the time results of 2000-m ergometer test were recorded after the race.

Eligibility Criteria:
Inclusion Criteria:

* Continuing to rowing sport actively
* Rowing age of at least 2 years
* Young men rowers aged between the 16-18 years

Exclusion Criteria:

* Acute injury in the lumbar region and lower extremity and/or presence of pain for more than 3 months,
* Surgical operation in the lumbar region and lower extremity region in the last 6 months,
* Over 18 years old or under 16 years old and less than 2 years of rowing age
Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease

The aim of this study was to evaluate the efficiency and safety of simultaneous islet-kidney transplantation in patients of type 1 diabetes with end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Islet transplantation can result in insulin independence with excellent metabolic control when glucocorticoid-free immunosuppression is combined with the infusion of an adequate islet mass. Alemtuzumab (Campath-1H ®) is a 150-kDa humanized IgG1 monoclonal antibody that targets the CD52 antigen. Prolonged lymphocyte depletion can be expected following alemtuzumab treatment.


Eligibility Criteria:
Inclusion Criteria:

* Male and female patients age 18 to 60 years of age.
* Ability to provide written informed consent.
* Clinical history compatible with type 1 diabetes (T1DM) as defined by the WHO guidelines(1999) on the Diagnosis and classification of Diabetes Mellitus.
* manifest signs and symptoms that are severe enough to be incapacitating.
* Basal C-peptide\<0.5ng/mL
* patients with poor diabetes control (HbA1c \>7% but \<12%)
* progressive diabetic complications.
* end-stage renal disease(serum creatinine\>450μmol/l)

Exclusion Criteria:

* age \<18 years or \>60 years
* diabetic history \<5 years
* BMI\>27
* body weight \>80kg
* exogenous insulin requirement \>1 unit/kg/day
* severe anemia (male \<8g/dl, female \<7g/dl)
* low white blood cell count (\<3000/dl)
* liver dysfunction
* Symptomatic peptic ulcer disease
* Any malignancy
* Active infection including hepatitis B, hepatitis C, HIV, or TB
* panel reactive antibody \>20%
* Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.
EGFR Mutations on ctDNA in Patients With Advanced NSCLC

The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed stage IIIB/IV NSCLC;
* Patient had received ≤ 1 prior systemic chemotherapy regimens;
* Provision of blood (plasma) sample for ctDNA testing;
* Patient must be able to comply with the protocol;

Exclusion Criteria:

* Prior received ≥2 systemic chemotherapy regimens;
* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);
* Histologically confirmed small cell lung cancer or other metastatic tumors;
* Patient with no histologic or cytological diagnosis;
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly

Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of patients with acromegaly in terms of both tumour control and biochemical remission

An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital, Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and biochemical control assessed by growth hormone measurements during an oral glucose tolerance test. Furthermore all other pituitary axes were tested for sufficiency and concomitant medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour control and biochemical remission profile, and most patient had subsequent withdrawal of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study will continue with a new update in approx 2 years

Eligibility Criteria:
Inclusion Criteria:

adults active acromegaly pituitary tumour on MRI biochemical activity -

Exclusion Criteria:

pregnancy no visible tumour on MRI

-
A Hybrid Type 2 Trial of Trauma-Focused Cognitive Behavioral Therapy and a Pragmatic Individual-Level Implementation Strategy

This research project is a hybrid type 2 effectiveness-implementation trial that simultaneously examines (1) the effectiveness of a trauma-focused intervention for youth in the education sector and (2) the impact of a theory-driven pragmatic implementation strategy designed to increase the adoption, fidelity, and sustainment of evidence-based treatments (EBTs). This trial will include 120 clinicians and 480 students, and it is designed to test the cost effectiveness and impact of Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) in a new setting that increases access to mental health care - schools (Aim 1); test the cost effectiveness, immediate impact, and sustained impact of the Beliefs and Attitudes for Successful Implementation in Schools (BASIS) implementation strategy on proximal mechanisms and implementation outcomes (Aims 2a, 2b, 2d); and conduct sequential mixed-methods data collection to explain residuals (i.e., clinicians whose implementation behavior is unaccounted for by the mediation model) (Aim 2c).


Eligibility Criteria:
Clinicians will be included if they (a) provide school-based services in a participating district; (b) have not previously received formal training in TF-CBT; and (c) are not actively receiving support to implement another trauma-focused intervention.

Students subjects will meet TF-CBT eligibility criteria, including (a) be within the TF-CBT developmental range (grades 3 -12), (b) have traumatic event exposure (e.g., exposure to violence), and (c) significant post-traumatic stress symptoms.
Short Term Evaluation of SLIC Screw in Treatment of Scapholunate Injury

The purpose of this retrospective-prospective clinical evaluation is to determine whether the SLIC Screw System provides provisional fixation to allow biological healing of the scapholunate interval.


Eligibility Criteria:
Inclusion Criteria:

* Subjects willing and able to comprehend and sign Informed Consent
* Subjects who have received the SLIC screw as part of the treatment for scapholunate ligament repair or scapholunate reduction
* Subjects with acute scapholunate injury, classified with Garcia-Elias Stage 1-4, OR Geissler Stage 1-3
* Subjects \>18 years of age at the time of surgery

Exclusion Criteria:

* Subject diagnosed with chronic scapholunate injury
* Subjects who underwent previous scapholunate procedure on the study wrist before implantation of the SLIC Screw System
* Subjects with active or latent infection at the time of surgery
* Subjects with sepsis at the time of surgery
* Subjects diagnosed with osteoporosis at the time of surgery
* Subjects with insufficient quantity and/or quality of bone
* Subjects with cartilage degeneration on the bones at the time of surgery
* Subjects with absence of potential for soft tissue healing at time of surgery, as documented by the investigator.
* Female Subjects known to be pregnant
* Subjects who were unable to follow postoperative care instructions, specifically, activity levels
* Subjects who are unable or unwilling to return for postoperative study visits
Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)

Hypothesis:

In France, approximately 12,000 new rectal cancers are diagnosed each year. Frequency is one and a half times higher in men than in women. The average age of diagnosis is 65. Unlike colon cancer, technical management remains challenging with unresolved operating difficulties. Morbidity of surgical procedures remains high with a very large number of preventive or curative stoma derivations.

Reference in surgical treatment is total excision of the rectum and its mesentery, followed by continuity restoration by immediate coloanal anastomosis (ACAI). In this procedure, rate of fistula that results is reported in the literature between 15 and 25%.

An alternative to ACAI is delayed coloanal anastomosis without reservoir (ACAD). Based on retrospective experiences, we form the hypothesis that ACAD offers a much lower rate of fistula (\<5%) and allows diminution of preventive stoma derivation practice. Morbidity and mortality are reduced, and patient's quality of life greatly improved. Direct costs (consumables intraoperative, hospitalization, stoma complications) and indirect (pocket-fitting stoma) are greatly reduced.

This study is a multicentre, two arms, phase 2 clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven rectal adenocarcinoma.
* Medium or lower rectum tumour requiring removal of the entire rectum and its mesorectum.
* T1 N+ or T2 N+ or T3 N+ or T3 N0 and M0 tumour.
* Age between 18 and 75 years .
* ASA ≤ 2.
* Sphincter continence compatible with coloanal anastomosis.
* Patients who received preoperative radiotherapy alone or chemotherapy and radiotherapy.
* Patient affiliated to social security.
* For patients of childbearing age, use of contraception.
* Patient information and consent for study participation

Exclusion Criteria:

* Other histology of rectal cancer.
* T1 N0 or T2 N0 or T4 tumour.
* Metastatic disease M1.
* History of cancer except cervix in situ carcinoma or skin basal cell carcinoma.
* Patient with psychological, social, family or geographical reasons who couldn't be treated or monitored regularly by the criteria of the study
* Patients deprived of liberty or under guardianship.
* Pregnant or nursing women.
Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears

RATIONALE: Written educational materials and counseling by phone may help promote follow-up care in women with abnormal Pap smears.

PURPOSE: This clinical trial is studying how well written educational information and phone calls work in increasing follow-up care in Hispanic women with abnormal Pap smears.

OBJECTIVES:

Primary

* Determine the reasons for nonadherence to follow-up in Hispanic women with abnormal Pap smear findings.
* Assess the effect of written educational information and phone calls on follow-up rate in these patients.

OUTLINE: This is a pilot, cross-sectional, controlled, multicenter study. Patients are sequentially assigned to 1 of 3 intervention groups.

* Group 1 (control): Patients complete a standardized Spanish survey questionnaire, assessing their demographic information, knowledge, attitudes, behaviors, experiences with cervical screening, past medical history, and prior treatment, either in person (for those who kept their colposcopy appointment) or over the telephone (for those who did not keep their colposcopy appointment). Additional questions are added for patients who did not keep their colposcopy appointment to test for differences and to learn the reasons for not keeping their appointment.
* Group 2 (written educational information): Patients receive notification of their colposcopy appointment and an educational letter about Pap smears, cervical cancer risk, and the purpose and procedure of colposcopy. They complete the standardized Spanish survey questionnaire as in group 1.
* Group 3 (phone call): Patients receive notification of their colposcopy appointment and a personal telephone call educating them about Pap smears, cervical cancer risk, and the purpose and procedure of colposcopy. They complete the standardized Spanish survey questionnaire as in group 1.

All patients are asked to agree to submit residual Pap smear fluid to the Comprehensive Cancer Center of Wake Forest University tumor bank, and be included in a tracking system to insure future follow-up communications.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Abnormal Pap smear findings indicating the need for further treatment at the colposcopy clinic
* Scheduled for colposcopy at the Comprehensive Cancer Center of Wake Forest University
* No history of invasive cervical cancer

PATIENT CHARACTERISTICS:

* Must be of Hispanic background, including any of the following:

  * Hispanic
  * Latino
  * Chicano
  * Mexican American
  * Puerto Rican
  * Cuban American

PRIOR CONCURRENT THERAPY:

* Not specified
Comparing Point of Care Clotting Tests in the OR Versus Standard Laboratory Clotting Tests

The purpose of this study is determine the agreement of point of care (POC) clotting tests (INR and aPTT) by the POC device by Hemochron Jr versus standard laboratory clotting tests (INR and aPTT) in patients undergoing elective cardiac surgery.

The study is a correlation between POC Hemochron Jr INR and aPTT with the standard.

Eligibility Criteria:
Inclusion Criteria:

* did not receive anticoagulants or clopidogrel within 5 days preoperatively

Exclusion Criteria:

* history of coagulopathy
* heparin resistance
* receiving heparin or warfarin
* hepatic or renal dysfunction
* pregnancy
* urgent or emergency cases
Darbepoetin Alfa MDS Companion Protocol

The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

This is a phase 3b, multi-centre, open-label, single-arm companion study to the MDS 20090160 study (NCT01362140) for the treatment of anaemic patients with MDS. Participants who completed the active-treatment period of the darbepoetin alfa MDS 20090160 study and met the eligibility criteria could be enrolled into this study to continue treatment of darbepoetin alfa for up to 73 weeks or until progression to acute myelogenous leukemia (AML), whichever occurs first.

Eligibility Criteria:
Inclusion Criteria:

* Subject or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/ procedures being initiated;
* Subject must continue long term follow up within parent study (20090160);
* Subject must have an ongoing clinically relevant erythroid response as assessed by the Investigator using current response criteria (ie, International Working Group (IWG) response criteria);

Exclusion Criteria:

* Transfusion dependence defined as receiving a total of ≥ 4 units of red blood cell (RBC) transfusion in the previous 8-week period prior to enrolment;
* Known diagnosis of acute myelogenous leukemia (AML) or marrow collagen fibrosis;
* Known refractory anaemia with excess blast-2 (RAEB-2);
* Known diagnosis of intermediate-2 or high risk MDS per International Prognostic Scoring System (IPSS);
* Subjects received thrombopoiesis-stimulating factors (eg, eltrombopag, romiplostim) in the MDS 20090160 study or planning to receive such agents during the study;
* Other protocol defined inclusion and exclusion criteria may apply.
Minor Troponin Elevations in Patients With Atrial Fibrillation

This study aims at identifying the etiology of troponin-T elevations in patients with atrial fibrillation visiting the emergency department.

The aim of this study is to identify the factors associated with minor cardiac troponin-T elevations in patients presenting in emergency department (ED) with atrial fibrillation (AF) diagnosis , and the possible implications it has on the patients prognosis. Data on 3394 patients from the Turku university hospital catchment area with diagnosis of AF on admission to ED and minor troponin-T elevation were analyzed. Patients were classified into three groups according to the troponin-T value: troponin \<15ng/l, 15-50ng/l and 51-100ng/l. Individual patient records were reviewed.

Eligibility Criteria:
Inclusion Criteria:

* two troponin T tests within 72 hours of ED admission
* Prior diagnosis of AF or AF at admission

Exclusion Criteria:

* Age \< 18 years
Acute Effects of Oral Carbohydrate and Fat Loads on Systemic Microvascular Endothelial Function in Healthy Individuals.

The present study was designed to evaluate vascular endothelial dysfunction resulting from the oral ingestion of high loads of sugar and fat meals in healthy individuals.

The chronic and elevated consumption of fat and carbohydrates is associated with the initiation and the progression of cardiovascular and metabolic diseases, including diabetes, obesity and metabolic syndrome. In general, chronic diseases are related to underlying modifiable cardiovascular risk factors, including high blood pressure, high plasma lipids and glucose, physical inactivity, overweight and obesity, as well as smoking habits.

Vascular endothelial dysfunction is one of the earliest findings in the pathophysiology of atherosclerosis and also an important predictor of cardiovascular events. Moreover, it has already been demonstrated that acute oral ingestion of high loads of sugar and fat meals induces transient vascular endothelial dysfunction, which over time could lead to cardiovascular disease.

Thus, the present study aimed at investigating the individual contributions of sugar and fat ingestion on systemic microvascular endothelial reactivity.

Eligibility Criteria:
Inclusion Criteria:

* healthy individuals presenting body mass index between 18.5 e 24.9 kg/m2

Exclusion Criteria:

* dysglycemia and dyslipidemia
* overweight and obesity
Colorectal Cancer in Crohn's Disease

Retrospective multicentre study. All patients with a diagnosis of Crohn's disease (CD) and operated for colorectal cancer (CRC) between 01/01/2010 and 01/01/2020 will be included in the dataset.

Data will include preoperative, intraoperative and postoperative variables, with long term follow up when feasible.

The study will focus on a comparison between patients treated with total proctocolectomy (TPC) and patients treated with subtotal colectomy (STC) or segmental resection (SR).

Primary endpoints will be oncologic outcomes, postoperative morbidity and mortality. Secondary endpoints include quality of life (QoL).


Eligibility Criteria:
Inclusion Criteria:

* All patients with a diagnosis of Crohn's disease and concomitant primary colorectal cancer who underwent surgery in an expert centre between 01/01/2010 and 01/01/2020

Exclusion Criteria:

* Patients who underwent non-oncologic segmental resection will be excluded from outcome analysis.
* Patients with known genetic colorectal cancer syndromes (eg. Familial Adenomatous Polyposis, Hereditary Non-Polyposis ColoRectal Cancer Syndrome)